Company / Inventory
Regeneron Pharmaceuticals Inventory History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Inventory
$3.2B
FY2025
5-year range
$2.0B / $3.2B
FY2021-FY2025
Trend
+3.7%
vs FY2024
Sector context
#8 of 105
Health Care
What the data says
Among 105 Health Care companies, Regeneron Pharmaceuticals is in the top 8% for inventory. Inventory has increased for 9 consecutive years, from $399M in FY2016 to $3.2B in FY2025.
Based on SEC 10-K filings.
$3.2B in FY2025 with a 5-year CAGR of +10.8%. Top quartile in the Health Care sector.
Improved from $2.6B to $3.2B over the past 2 years.
Health Care sector context is included.
Inventory over time
Growth rates
- 3-Year CAGR
- +10.0%
- 5-Year CAGR
- +10.8%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 105This company $3.2B Sector average $885.3M
▼
+261.6% above sector average
Key checks
Key Insights
- Regeneron Pharmaceuticals's inventory has grown for 9 consecutive years.
- 5-year CAGR of +10.8%, indicating consistent growth.
- In FY2025, inventory increased 3.7% year-over-year.
- Ranks #8 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | InventoryValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.2B | +3.7% |
| FY2024 | $3.1B | +19.6% |
| FY2023 | $2.6B | +7.4% |
| FY2022 | $2.4B | +23.1% |
| FY2021 | $2.0B | +1.8% |
| FY2020 | $1.9B | +35.4% |
| FY2019 | $1.4B | +23.0% |
| FY2018 | $1.2B | +58.5% |
| FY2017 | $726.1M | +81.8% |
| FY2016 | $399.4M | +67.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026